Cost Analysis of Residual Viremia Detected by Two Real-Time Pcr Assays For Response-Guided (Dual Or Triple) Therapy of Hcv Genotype 1 Infection

Paolini, Davide; Lunghi, G.; Aghemo, Alessio; Dionisi, Matteo; Colombo, Massimo; Torresani, Erminio

doi:10.1016/j.jval.2015.09.1501

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From the economic perspective, cost-effectiveness and cost-sustainability have been studied in Italy [12][13][14][15], and the data demonstrated the economic efficiency and sustainability of the direct-acting antiviral (DAA) therapy investment. Apart from these studies, no specific analysis has estimated the economic consequences of the Italian National Health System (NHS) investment and access to treatment.…”

Section: Introductionmentioning

confidence: 99%

Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

et al. 2018

View full text Add to dashboard Cite

Your article is protected by copyright and all rights are held exclusively by Springer Nature Switzerland AG. This e-offprint is for personal use only and shall not be selfarchived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com".

show abstract

Section: Introductionmentioning

confidence: 99%

Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

et al. 2018

View full text Add to dashboard Cite

show abstract

Cost Analysis of Residual Viremia Detected by Two Real-Time Pcr Assays For Response-Guided (Dual Or Triple) Therapy of Hcv Genotype 1 Infection

Abstract: The results of this study indicate that bedaquiline is a cost-effective option for the treatment of MDR (including XDR-TB patients) in the Korean settings when compared to standard treatment alone.

Cited by 1 publication

References 0 publications

Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

Contact Info

Product

Resources

About